Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$248.80
+0.0%
$254.66
$190.75
$267.47
$439.52B0.296.64 million shs316,196 shs
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$64.73
+0.1%
$63.23
$42.52
$68.64
$132.19B0.2311.87 million shs531,846 shs
Pfizer Inc. stock logo
PFE
Pfizer
$27.86
+0.3%
$26.13
$23.58
$29.21
$158.74B0.3441.31 million shs3.32 million shs
Zoetis Inc. stock logo
ZTS
Zoetis
$73.48
-0.1%
$75.61
$71.00
$152.00
$30.37B0.735.67 million shs547,191 shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-2.94%-4.28%+1.19%+10.47%+18.47%
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
-3.32%-3.13%+0.00%+16.20%+38.45%
Pfizer Inc. stock logo
PFE
Pfizer
-2.25%-2.77%+4.03%+8.49%+13.18%
Zoetis Inc. stock logo
ZTS
Zoetis
-2.82%-4.71%+1.43%-9.61%-51.56%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$248.80
+0.0%
$254.66
$190.75
$267.47
$439.52B0.296.64 million shs316,196 shs
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$64.73
+0.1%
$63.23
$42.52
$68.64
$132.19B0.2311.87 million shs531,846 shs
Pfizer Inc. stock logo
PFE
Pfizer
$27.86
+0.3%
$26.13
$23.58
$29.21
$158.74B0.3441.31 million shs3.32 million shs
Zoetis Inc. stock logo
ZTS
Zoetis
$73.48
-0.1%
$75.61
$71.00
$152.00
$30.37B0.735.67 million shs547,191 shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-2.94%-4.28%+1.19%+10.47%+18.47%
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
-3.32%-3.13%+0.00%+16.20%+38.45%
Pfizer Inc. stock logo
PFE
Pfizer
-2.25%-2.77%+4.03%+8.49%+13.18%
Zoetis Inc. stock logo
ZTS
Zoetis
-2.82%-4.71%+1.43%-9.61%-51.56%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.88
Moderate Buy$275.9510.92% Upside
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.56
Moderate Buy$66.062.04% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.19
Hold$28.281.48% Upside
Zoetis Inc. stock logo
ZTS
Zoetis
2.32
Hold$101.0837.56% Upside

Current Analyst Ratings Breakdown

Latest PFE, BMY, ZTS, and ABBV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Reiterated RatingBuy
8/31/2026
Pfizer Inc. stock logo
PFE
Pfizer
UpgradeHold (C-)Hold (C)
8/25/2026
Zoetis Inc. stock logo
ZTS
Zoetis
Lower Price TargetBuy$104.00 ➝ $94.00
8/25/2026
Zoetis Inc. stock logo
ZTS
Zoetis
Set Price Target$94.00
8/20/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Boost Price TargetOverweight$298.00 ➝ $303.00
8/20/2026
Zoetis Inc. stock logo
ZTS
Zoetis
Lower Price TargetHold$85.00 ➝ $80.00
8/18/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
UpgradeHold (C+)Buy (B-)
8/17/2026
Pfizer Inc. stock logo
PFE
Pfizer
DowngradeHold (C)Hold (C-)
8/17/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Boost Price TargetOverweight$295.00 ➝ $300.00
8/13/2026
AbbVie Inc. stock logo
ABBV
AbbVie
UpgradePeer PerformOutperform$300.00
8/11/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Boost Price TargetNeutral$218.00 ➝ $247.00
(Data available from 9/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$61.16B7.19$14.70 per share16.93($1.83) per share-135.96
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$49.19B2.69$7.88 per share8.22$9.09 per share7.12
Pfizer Inc. stock logo
PFE
Pfizer
$63.70B2.49$4.31 per share6.47$15.26 per share1.83
Zoetis Inc. stock logo
ZTS
Zoetis
$9.47B3.21$7.33 per share10.02$7.56 per share9.72
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.23B$3.5470.2715.411.169.80%-422.07%14.34%10/30/2026 (Estimated)
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$7.05B$4.5414.2510.050.3218.87%66.90%14.74%10/29/2026 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$0.7636.659.481.916.80%19.63%8.46%11/3/2026 (Estimated)
Zoetis Inc. stock logo
ZTS
Zoetis
$2.67B$6.0712.1111.611.7727.49%74.89%18.59%11/3/2026 (Estimated)

Latest PFE, BMY, ZTS, and ABBV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Zoetis Inc. stock logo
ZTS
Zoetis
$1.85$1.87+$0.02$1.65$2.50 billion$2.47 billion
8/4/2026Q2 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.6820$0.77+$0.0880-$0.04$14.40 billion$15.03 billion
7/31/2026Q2 2026
AbbVie Inc. stock logo
ABBV
AbbVie
$3.61$3.65+$0.04$2.03$16.80 billion$16.99 billion
7/30/2026Q2 2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$1.60$2.04+$0.44$1.62$11.74 billion$12.97 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.922.78%+6.80%195.48%53 Years
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$2.523.89%+1.61%55.51%17 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.17%-13.20%226.32%16 Years
Zoetis Inc. stock logo
ZTS
Zoetis
$2.122.89%+20.11%34.93%14 Years

Latest PFE, BMY, ZTS, and ABBV Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/24/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.01%7/24/20267/24/20269/1/2026
6/18/2026
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.732.83%7/15/20267/15/20268/14/2026
6/17/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
quarterly$0.634.34%7/2/20267/2/20268/3/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
N/A
0.81
0.69
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
1.89
1.53
1.38
Pfizer Inc. stock logo
PFE
Pfizer
0.71
1.27
0.96
Zoetis Inc. stock logo
ZTS
Zoetis
2.87
3.08
1.84

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
76.41%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Zoetis Inc. stock logo
ZTS
Zoetis
92.80%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.06%
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
0.05%
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
Zoetis Inc. stock logo
ZTS
Zoetis
0.22%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
57,0001.77 billion1.77 billionOptionable
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
32,5002.04 billion2.04 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable
Zoetis Inc. stock logo
ZTS
Zoetis
14,500413.22 million412.32 millionOptionable

Recent News About These Companies

HighTower Advisors LLC Sells 166,492 Shares of Zoetis Inc. $ZTS
HB Wealth Management LLC Boosts Holdings in Zoetis Inc. $ZTS
Carmignac Gestion Buys Shares of 1,575,700 Zoetis Inc. $ZTS
Zoetis (ZTS) Shares Drop After Earnings Revision
Amundi Increases Holdings in Zoetis Inc. $ZTS
Nykredit A S Purchases New Shares in Zoetis Inc. $ZTS
Zoetis Inc. (NYSE:ZTS) Given Average Recommendation of "Hold" by Brokerages
AlphaGrep UK Ltd Buys New Position in Zoetis Inc. $ZTS

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AbbVie stock logo

AbbVie NYSE:ABBV

$248.80 +0.02 (+0.01%)
As of 10:28 AM Eastern
This is a fair market value price provided by Massive. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Bristol Myers Squibb stock logo

Bristol Myers Squibb NYSE:BMY

$64.73 +0.04 (+0.07%)
As of 10:28 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Pfizer stock logo

Pfizer NYSE:PFE

$27.86 +0.07 (+0.27%)
As of 10:28 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Zoetis stock logo

Zoetis NYSE:ZTS

$73.48 -0.08 (-0.11%)
As of 10:28 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.